| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.14 | 0.3 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.17 | 0.3 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.035 | 0.3 |